In addition to these direct mechanisms of GLP-1 analogs on hepatocytes, GLP-1 analogs have been shown to significantly reduce serum C-reactive protein, interleukin-6, and tumor necrosis factor-α [42–44], which is involved in liver inflammation, development of hepatocellular carcinoma, and the progression of NASH. Here, IL6 is linked to metabolic dysfunction-associated steatohepatitis.